We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer.
- Authors
Chen, Shaoliang; Yu, Like; Jiang, Changying; Zhao, Yan; Sun, Da; Li, Shenyu; Liao, Guoqing; Chen, Yangchun; Fu, Qing; Tao, Qun; Ye, Dan; Hu, Peisheng; Khawli, Leslie A; Taylor, Clive R; Epstein, Alan L; Ju, Dian Wen
- Abstract
Tumor necrosis treatment (TNT) uses degenerating tumor cells and necrotic regions of tumors as targets for radioimmunotherapy. Previous studies in animal tumor models and clinical trials have demonstrated that when linked to the therapeutic radionuclide iodine-131, recombinant chimeric TNT antibody ((131)I-chTNT) can deliver therapeutic doses to tumors regardless of the location or type of malignancy. Therapeutic efficacy and toxicity of (131)I-chTNT in advanced lung cancer patients were studied in this pivotal registration trial.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Vol 23, Issue 7, p1538
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2005.06.108